Building on clinical and mechanistic insights from our experience over the past 15 years, the ITN has a focused and deliberate approach to achieveing immune tolerance in asthma and allergy, autoimmune diseases, type 1 diabetes and solid organ transplantation.
To ensure that the Network’s clinical research meets the goal of achieving immune tolerance in each therapeutic area, ITN studies are driven by testable mechanistic hypotheses. Mechanistic studies are designed to accompany each clinical trial and ensure that, no matter what the clinical outcome, each study will yield valuable information and advance our understanding and progress toward achieving immune tolerance.
ITN's strategic plans for each therapeutic area include the underlying scientific principles, priority therapeutic concepts and specific clinical and mechanistic goals: